Cart
sales@molnova.com
Mitoquidone
CAS No. 91753-07-0
Mitoquidone( —— )
Catalog No. M36195 CAS No. 91753-07-0
Mitoquidone, a novel pentacyclic pyrroloquinone, is a potential anticancer agent. Mitoquidone showed good activity in a range of experimental solid tumour models and did not exhibit significant cytotoxicity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 200 | In Stock |
|
| 10MG | 295 | In Stock |
|
| 25MG | 557 | In Stock |
|
| 50MG | 753 | In Stock |
|
| 100MG | 1042 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 2093 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMitoquidone
-
NoteResearch use only, not for human use.
-
Brief DescriptionMitoquidone, a novel pentacyclic pyrroloquinone, is a potential anticancer agent. Mitoquidone showed good activity in a range of experimental solid tumour models and did not exhibit significant cytotoxicity.
-
DescriptionMitoquidone (GR-30921), a pentacyclic pyrroloquinone, is a potent anticancer agent.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number91753-07-0
-
Formula Weight299.32
-
Molecular FormulaC20H13NO2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1C2=C3N(C=C2C(=O)C=4C1=CC=CC4)CC=5C(C3)=CC=CC5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. P A Speth, et al. Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitoquidone. Cancer Chemother Pharmacol. 1988;21(4):343-6. ?
molnova catalog
related products
-
PF-1355
PF-1355 is a selective 2-thiouracil mechanism-based MPO inhibitor. PF-1355 is used for treatment of vasculitic diseases.
-
Heteroclitin C
Heteroclitin C is a Lignans product that can be isolated from the stems of Kadsura heteroclita.
-
(S,R,S)-AHPC-PEG2-NH...
(S,R,S)-AHPC-PEG2-NH2 hydrochloride (VH032-PEG2-NH2 hydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.
